Comparison of different antibiotic treatment in children with community acquired pneumonia: a comparative study

Nasima Banu, Vijay Kumar Sukhani


Background: community acquired pneumonia also known as CAP refers to pneumonia contracted by a person with little contact with the healthcare system. Narrow spectrum antibiotics are generally considered to be the first line of treatment however there is considerable concern about the emerging resistance among the usual CAP pathogens to the most commonly used antimicrobial agents. The objective of this study was comparison of different antibiotic treatment in children with community-acquired pneumonia.

Method: A total of 100 paediatric patients who were admitted to the Emergency Department of medical institution with suspicion of pneumonia were included in the study. All the patients will be divided broadly into two study groups with 50 patients in each group. Group 1 patients were given intravenous amoxiclav, while Group 2 received intravenous ceftriaxone.

Results: In present study subjects from, Group 1 i.e. amoxclav group 42% had fever, i.e. 24% were suffering from tachypnea and only 4% suffered from tachycardia and abnormal was found in 20/50 patients. Whereas in Group 2 -60% were suffering from fever, 16/50 i.e. 32% has tacypnea, 3/50 i.e. 6% had tachycardia and 16/50 i.e. 32 had abnormal WBC. In present study abnormal WBC was found to be more in first group.

Conclusions: Ceftriaxone and amoxiclav can be used successfully in treatment of CAP.


Antibiotics, Broad spectrum, CAP, Pneumonia

Full Text:



Lee GE, Lorch SA, Sheffler-Collins S, Kronman MP, Shah SS. National hospitalization trends for pediatric pneumonia and associated complications. Pediatr. 2010;126(2):204-1.

Mishra AB, Gagan Bihari Be- hera. Community acquired pneumonia, detection and prevention: a hospital based descriptive study. Int J Contemp Med Res. 2016;3(4):1127-9.

Mohanty D, Routray SS, Mishra D, Das A. Ventilator associated pneumonia in a ICU of a tertiary care hospital in India. Int J Contemp Med Res. 2016;3(4):1046-9.

Barlow G, Nathwani D, Davey P. The effect of implementing the British Thoracic Society community-acquired pneumonia guidelines on antibiotic prescribing and costs in a UK teaching hospital. Clin Microbiol Infect. 2006;12:498-500.

Rahav G, Toledano Y, Engelhard D, Simhon A, Moses AE, Sacks T, et al. Invasive pneumococcal infections: A comparison between adults and children. Rev Mol Med. 1997;76:295-303.

Newman RE, Hedican EB, Herigon JC, Williams DD, Williams AR. Impact of a guideline on management of children hospitalized with community-acquired pneumonia. Newland JG Pediatr. 2012;129(3):e597-604.

Collini P, Beadsworth M, Anson J, Neal T, Burnham P, Deegan P, et al. Community-acquired pneumonia: Doctors do not follow national guidelines. Postgrad Med J. 2007;83:552-5.

Juven T, Mertsola J, Waris M, Leinonen M, Ruuskanen O. Clinical response to antibiotic therapy for community-acquired pneumonia. Eur J Pediatr. 2004;163:140-4.

Feikin DR, Schuchat A, Kolczak M, Barrett NL, Harrison LH, Lefkowitz L, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health. 2000;90:223-9.

Gotfried MH. Management of Community-Acquired Pneumonia. Supplement to Journal of the association of physicians of india. 2013;6:61-6.

Balgos AA, Rodriguez-Gomez G, Nasnas R, Mahasur AA, Margono BP, Tinoco-Favila JC. Efficacy of twice-daily amoxycillin/clavulanate in lower respiratory tract infections. Int J Clin Pract. 1999;53:325-30.

Martin M, Moore L, Quilici S, Decramer M, Simoens S. A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumoniataking into account resistance in Belgium. Curr Med Res Opin. 2008;24(3):737-51.

Odoemene IF, Enwere OO. Susceptibility pattern to common antibiotics of intestinal escherichia coli from slaughtered commercially grown chickens. Int J Contemp Med Res. 2018;5(3):C25-C30.